SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...
In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...
Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results